- Analysts9
- Implied upside+11.4%
- Target range$63.00 to $103.00
- EPS expected$0.07 -85%
- A year ago$0.49
- Revenue expected$124.3M +6.4%
- Estimate range$0.07 to $0.08
SEC filings
| Form | Filed | Description |
|---|---|---|
| SCHEDULE 13G/A | August 7, 2026 | View on EDGAR |
| 10-Q | August 3, 2026 | 10-Q |
| 8-K | August 3, 2026 | 8-K |
| SCHEDULE 13G | July 28, 2026 | View on EDGAR |
| 25-NSE | July 21, 2026 | View on EDGAR |
| 4 | July 1, 2026 | View on EDGAR |
| 4 | June 23, 2026 | View on EDGAR |
| 4 | June 23, 2026 | View on EDGAR |
Our WGS coverage
Frequently asked questions
When does WGS report earnings?
GeneDx Holdings Corp. (WGS) is scheduled to report quarterly results on October 27, 2026 (estimated). The 5-analyst consensus is $0.07 per share on revenue of $124.3M for the quarter ending September 30, 2026, against $0.49 and $116.7M a year earlier. The date is an estimate from past reporting patterns and can move until the company confirms it.
What do analysts expect for WGS?
9 analysts cover GeneDx Holdings Corp. (WGS). The consensus rating is Strong buy. The average price target is $85.89, in a range of $63.00 to $103.00.
Are insiders buying or selling WGS?
We have no qualifying Form 4 insider purchases or sales on record for GeneDx Holdings Corp. (WGS). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Where can I see WGS SEC filings?
Recent filings are listed on this page, newest first. The latest is a SCHEDULE 13G/A filed August 7, 2026.
